A novel model-based approach for dose determination of glycopyrronium bromide in COPD
<p>Abstract</p> <p>Background</p> <p>Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimen...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-12-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2466/12/74 |